Kymera Therapeutics (KYMR) Current Leases (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Current Leases of $1.7 million for Q1 2026, up 9.11% year-over-year from $1.6 million in Q1 2025, and down 85.75% quarter-over-quarter from $11.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Current Leases (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Current Leases for 8 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 9.11% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 9.11% YoY), while the FY2025 annual figure was $11.9 million, up 686.63% from the prior year.
- Current Leases slipped to $1.7 million in Q1 2026 per KYMR's latest filing, from $11.9 million in the prior quarter.
- Across five years, Current Leases topped out at $11.9 million in Q4 2025 and bottomed at $1.0 million in Q3 2023.
- Historically, Current Leases has averaged $3.4 million across 5 years, with a median of $1.9 million in 2025.
- On a YoY basis, Current Leases climbed as much as 686.63% in 2025 and fell as far as 83.37% in 2025.
- Kymera Therapeutics' Current Leases stood at $1.4 million in 2022, then retreated by 9.3% to $1.3 million in 2023, then gained by 18.87% to $1.5 million in 2024, then soared by 686.63% to $11.9 million in 2025, then sank by 85.75% to $1.7 million in 2026.
- Business Quant data shows KYMR's Current Leases at $1.7 million in Q1 2026, $11.9 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 12.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.12 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 11.94 Mn |
| Sep 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 11.42 Mn |
| Mar 31, 2024 | 8.76 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 2.52 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 2.48 Mn |
| Dec 31, 2021 | 2.46 Mn |
| Sep 30, 2021 | 1.19 Mn |